Alain Antoine Mina1, Brady Stein2,3. 1. Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA. 2. Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA. brady.stein@nm.org. 3. , Chicago, USA. brady.stein@nm.org.
Abstract
PURPOSE OF REVIEW: To discuss the impact that next-generation sequencing has had on myeloproliferative neoplasm prognosis and treatment response. RECENT FINDINGS: Extended genetic testing has led to a more comprehensive understanding of the mutational landscape in the myeloproliferative neoplasms. More refined prognostic models that predict disease course have therefore been developed. In myelofibrosis, this has led to a more nuanced prognostic assessment which is a necessary tool for the identification of potential transplant patients. The extended molecular profile may also help set expectations for ruxolitinib response duration. In essential thrombocythemia and polycythemia vera, elucidation of the molecular landscape beyond driving mutations may identify patients at risk for more rapid progression. However, results from testing are less likely to lead to action, at least in the current era. Use of next-generation sequencing has become routine in myelofibrosis, as a means of identifying patients at highest risk for progression, who may be eligible for transplantation. Extended genetic sequencing is still investigational in essential thrombocytosis and polycythemia vera, and not recommended by guidelines.
PURPOSE OF REVIEW: To discuss the impact that next-generation sequencing has had on myeloproliferative neoplasm prognosis and treatment response. RECENT FINDINGS: Extended genetic testing has led to a more comprehensive understanding of the mutational landscape in the myeloproliferative neoplasms. More refined prognostic models that predict disease course have therefore been developed. In myelofibrosis, this has led to a more nuanced prognostic assessment which is a necessary tool for the identification of potential transplant patients. The extended molecular profile may also help set expectations for ruxolitinib response duration. In essential thrombocythemia and polycythemia vera, elucidation of the molecular landscape beyond driving mutations may identify patients at risk for more rapid progression. However, results from testing are less likely to lead to action, at least in the current era. Use of next-generation sequencing has become routine in myelofibrosis, as a means of identifying patients at highest risk for progression, who may be eligible for transplantation. Extended genetic sequencing is still investigational in essential thrombocytosis and polycythemia vera, and not recommended by guidelines.
Entities:
Keywords:
Essential thrombocythemia; Myelofibrosis; Myeloproliferative neoplasms; Next-generation sequencing; Polycythemia vera
Authors: Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi Journal: N Engl J Med Date: 2010-09-16 Impact factor: 91.245
Authors: Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda Journal: N Engl J Med Date: 2005-04-28 Impact factor: 91.245
Authors: Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi Journal: Blood Date: 2008-11-06 Impact factor: 22.113
Authors: Ralph Tiedt; Hui Hao-Shen; Marta A Sobas; Renate Looser; Stephan Dirnhofer; Jürg Schwaller; Radek C Skoda Journal: Blood Date: 2007-12-26 Impact factor: 22.113
Authors: François Delhommeau; Sabrina Dupont; Véronique Della Valle; Chloé James; Severine Trannoy; Aline Massé; Olivier Kosmider; Jean-Pierre Le Couedic; Fabienne Robert; Antonio Alberdi; Yann Lécluse; Isabelle Plo; François J Dreyfus; Christophe Marzac; Nicole Casadevall; Catherine Lacombe; Serge P Romana; Philippe Dessen; Jean Soulier; Franck Viguié; Michaela Fontenay; William Vainchenker; Olivier A Bernard Journal: N Engl J Med Date: 2009-05-28 Impact factor: 91.245
Authors: Nils H Thoennissen; Utz O Krug; Dhong Hyun Tony Lee; Norihiko Kawamata; Gabriela B Iwanski; Terra Lasho; Tamara Weiss; Daniel Nowak; Maya Koren-Michowitz; Motohiro Kato; Masashi Sanada; Lee-Yung Shih; Arnon Nagler; Sophie D Raynaud; Carsten Müller-Tidow; Ruben Mesa; Torsten Haferlach; D Gary Gilliland; Ayalew Tefferi; Seishi Ogawa; H Phillip Koeffler Journal: Blood Date: 2010-01-12 Impact factor: 22.113